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Promoter region hypermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in
many human cancers. Previously, to identify candidate epigenetically inactivated TSGs in renal cell carcinoma (RCC), we monitored
changes in gene expression in four RCC cell lines after treatment with the demethylating agent 5-azacytidine. This enabled us to
identify HAI-2/SPINT2 as a novel epigenetically inactivated candidate RCC TSG. To identify further candidate TSGs, we undertook
bioinformatic and molecular genetic evaluation of a further 60 genes differentially expressed after demethylation. In addition to HAI-2/
SPINT2, four genes (PLAU, CDH1, IGFB3 and MT1G) had previously been shown to undergo promoter methylation in RCC. After
bioinformatic prioritisation, expression and/or methylation analysis of RCC cell lines±primary tumours was performed for 34 genes.
KRT19 and CXCL16 were methylated in RCC cell lines and primary RCC; however, 22 genes were differentially expressed after
demethylation but did not show primary tumour-specific methylation (methylated in normal tissue (n¼1); methylated only in RCC
cell lines (n¼9) and not methylated in RCC cell lines (n¼12)). Re-expression of CXCL16 reduced growth of an RCC cell line in vitro.
In a summary, a functional epigenomic analysis of four RCC cell lines using microarrays representing 11000 human genes yielded both
known and novel candidate TSGs epigenetically inactivated in RCC, suggesting that this is valid strategy for the identification of novel
TSGs and biomarkers.
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Renal cell carcinoma (RCC) is a heterogeneous disorder. Most
(B75%) of the tumours are classified as clear cell (conventional)
and the next most frequent subtype is papillary RCC (B15% of all
cases) (Kovacs et al, 1997). The most frequent genetic event in the
evolution of clear cell RCC is inactivation of the VHL tumour
suppressor gene (TSG) (Latif et al, 1993; Foster et al, 1994; Herman
et al, 1994; Clifford et al, 1998), but epigenetic inactivation of TSGs
by methylation of CpG dinucleotides in the promoter region has
also been implicated in the pathogenesis of RCC (Morrissey et al,
2001; Dallol et al, 2002; Morris et al, 2003). Tumour suppressor
gene promoter methylation has been studied most extensively in
colorectal cancer, but TSGs that are frequently methylated in
human cancers (e.g. p16
ink4a, DAPK, NORE1A, MGMT, SDHB,
RARB2 and CDH13) are infrequently methylated in RCC (Morris
et al, 2003). This observation prompted us to speculate that,
compared to other tumour types, a different repertoire of TSGs
might undergo epigenetic inactivation in RCC. Therefore, to
identify candidate novel epigenetically inactivated RCC TSGs,
we performed a gene expression profiling of four RCC cell
lines treated with the demethylated agent 5-azacytidine (5-AZA)
(Morris et al, 2005). Analysis of genes differentially expressed
before and after demethylation led us to identify HAI-2/SPINT2 as
a novel epigenetically inactivated RCC TSG (Morris et al, 2005).
In this study, we report the further analysis of our functional
epigenomic screen to identify genes relevant in development
of RCC.
MATERIALS AND METHODS
Cell Lines, 5-AZA-dC treatment and microarray analysis
Full details of the gene expression microarray experiments on four
RCC cell lines (KTCL26, SKRC39, SKRC45 and SKRC47) have been
described previously (Morris et al, 2005). All RCC cell lines
(KTCL26, RCC4, UMRC2, UMRC3, SKRC18, SKRC39, SKRC45,
SKRC47, SKRC54, 786-0 and Caki-1) analysed in this study were
routinely maintained in DMEM (Invitrogen, San Diego, CA, USA)
supplemented with 10% FCS at 371C, 5% CO2. The demethylating
agent 5-AZA-dC (Sigma, Gillingham, UK) was freshly prepared in
ddH2O and filter sterilised. Cell lines were plated in 75-cm
2 flasks
in DMEM supplemented with 10% FCS at differing densities,
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sdepending upon their replication factor, to ensure that both
control and 5-AZA-dC-treated lines reached approximately 75%
confluency at the point of RNA extraction. Twenty-four hours
later, cells were treated with 5mM 5-AZA-dC. The medium was
changed 24h after treatment and then changed again after 72h.
RNA was prepared 5 days after treatment using RNABee (AMS
Biotechnology, Oxon, UK).
Patients and samples
DNA from a total of 127 primary RCCs and 6 non-cancer-related
kidneys was analysed. Local ethics committees approved the
collection of samples and informed consent was obtained from
each patient.
RT–PCR conditions
PCR cycling conditions consisted of an initial denaturing step of
951C for 5min, followed by 30 cycles of 951C denaturing at 45s,
primer annealing at 55–601C (gene-dependent) and product
extension at 721C for 45s. Semiquantitative analysis of expression
was performed using LabWorks software (Ultraviolet products,
Upland, CA, USA). GAPDH primers were 50TGAAGGTCGGAGT
CAACGGATTTGGT30 and 50CATGTGGGCCATGAGGTCCACC
AC30 (other RT–PCR primers and conditions upon request).
Bisulphite modification and methylation analysis
Bisulphite DNA sequencing was performed as described previously
(Morris et al, 2003). Briefly, 0.5–1.0mg of genomic DNA was
denatured in 0.3 M NaOH for 15min at 371C, and then
unmethylated cytosine residues were sulphonated by incubation
in 3.12 M sodium bisulphite (pH 5.0; Sigma)/5mM hydroquinone
(Sigma) in a thermocycler (Thermo Fisher Scientific, Waltham,
MA, USA) for 20 cycles of 30s at 991C and 15min at 501C. The
sulphonated DNA was recovered using the Wizard DNA cleanup
system (Promega, Southampton, UK) in accordance with the
manufacturer’s instructions. The conversion reaction was com-
pleted by desulphonating in 0.3 M NaOH for 10min at room
temperature. The DNA was ethanol-precipitated and resuspended
in water.
Promoter methylation analysis
CpG islands were identified on the human genome browser and
putative promoter regions were predicted by Promoter Inspector
software (Genomatix, www.genomatix.de). Primer details are
shown in Supplementary Table 1.
Plasmid constructs and colony formation assay
The CXCL16 expression construct was made by cloning the full-
length human CXCL16 coding region from the SKRC 18 kidney
cell line, into the EcoR1–BamHII sites of pCDNA3.1 vector
(Invitrogen). Plasmid constructs were verified by sequencing. Six
micrograms of empty vector or 6.8mg (equal molar amounts) of
expression vector was transfected, by calcium phosphate method,
into 5 10
5 SKRC39 cells. Forty-eight hours after transfection,
cells were seeded in a serial dilution and maintained in DMEM and
10% foetal bovine serum supplemented with 1mgml
 1 G418
(Gibco, Invitrogen, Paisley, UK). Surviving colonies were stained
with 0.4% crystal violet (Sigma) in 50% methanol, 21 days after
initial seeding, and counted. Each transfection was carried out in
triplicate. Additionally, replicate experiments were carried out to
obtain further clones for expression analysis.
RESULTS
Identification and evaluation of differentially expressed
genes after demethylation of RCC cell lines
A total of 56 genes (of 11000 transcripts analysed), each with a
50 CpG island, that demonstrated 45-fold increased expression in
one cell line or 42-fold in multiple cell lines were identified as
candidate epigenetically inactivated RCC TSGs. In addition to
SPINT2, four further genes (CDH1, PLAU, IGFB3 and MT1G) had
previously been reported to undergo promoter region hyper-
methylation in RCC tumours (Yoshiura et al, 1995; Morris et al,
2003; Ibanez de Caceres et al, 2006). As we wished to identify novel
genes, these were not analysed further. After bioinformatic
evaluation (e.g. renal tissue specific expression patterns (array
express (www.ebi.ac.uk/arrayexpress/), human genome browser
(www.genome.ucsc.edu)), analysis of CpG islands for the presence
of predicted promoter regions (www.genomatix.de) and considera-
tion of likely role in tumorigenesis), 34 genes were selected for
analysis of expression and/or CpG island methylation status in
RCC cell lines±primary RCC tumours.
After analysis of expression pre- and post-treatment with 5-AZA
in up to 11 RCC cell lines, nine genes (ATF5, SLC1A4, ID3, STC2,
DUSP6, SEMA3C, CD44, HMGA1 and IRF7) were excluded from
further investigation as they were not commonly silenced in the
pretreatment cell lines (data not shown).
Promoter region methylation analysis of RCC cell lines and
tumours
All genes analysed had a 50 CpG island (as identified by the human
genome browser (http://genome.ucsc.edu/)) and promoter
regions were predicted by Genomatix promoter inspector software
(http://www.genomatix.de/). The methylation status of 50 CpG
island promoter regions were analysed by direct sequencing of
bisulphate-modified DNA of RCC cell lines and primary tumours
for 25 genes. Methylation of 50 CpG dinucleotides was rare
(ICAM1, IGSF4, EHM2, CLDN1, MUC1, SEMA5A) or absent (CTGF,
PHD3, RRM2, PMAIP1, GPR39, MYL2, BAP1, SLC25A21, FBLN1,
H2B, ECE1, FZD8) for 18 genes. For ICAM1, IGSF4, EHM2, CLDN1
and MUC1, no methylation was detected in 20 sporadic RCC
tumours. These findings suggest that the alterations in expression
after demethylation observed for these 18 genes were caused either
by (a) methylation of other in cis regulatory regions or (b) that
expression of these genes might be regulated by genes that were
epigenetically inactivated.
Seven genes demonstrated promoter region hypermethylation
concordant with gene expression in RCC cell lines (e.g. KTN19;
Figures 1A–C). Four of the seven genes (SST, PTGS1, ISG15,
THY1) were frequently methylated in RCC cell lines (Table 1) but
were not methylated in primary RCC (n¼20) and although ENG
was frequently methylated in RCC cell lines and primary tumours
(Table 1), methylation was also detected in adjacent normal tissues
and in normal renal tissue from patients without cancer (n¼6).
Two of the seven genes, CXCL16 and KTN19, demonstrated
frequent promoter region hypermethylation in RCC cell lines (40
and 62%, respectively) and in primary RCCs (42% (n¼62) and
38% (n¼66), respectively, but not in normal renal tissue from
patients without cancer (n¼6). For primary RCC with KTN19
promoter methylation, methylation was rarely (14%, 3/22) detected
in the adjacent normal tissue. In contrast, for tumours with
CXCL16 methylation (but not for unmethylated tumours),
methylation was also detected in the adjacent normal tissue.
We have expanded our previous analysis of HAI-2/SPINT2
promoter methylation in RCC (38%) to incorporate all tumours
analysed for KTN19 and CXCL16 promoter methylation. However,
no significant correlation was detected between methylation at
SPINT2, KTN19 and CXCL16 (P40.1) (data not shown).
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Figure 1 Tumour-specific KRT19 promoter methylation. (A) Schematic of CpG island and predicted promoter region in relation to the KRT19 gene.
(B) RT–PCR analysis of KTN19 shows silencing in five RCC cell lines. Expression is reactivated in four lines following treatment with 5-AZA. (C) Promoter
region methylation analysis by direct sequencing indicates that methylation correlates with gene silencing. (D) Methylation correlated to expression in
tumours; compare the methylation status of samples 15T and 30T with expression by RT–PCR. T, tumour, M, mehtylated promoter, U, unmethylated
promoter.
Table 1 Genes differentially expressed and frequently methylated in cell lines and/or tumours
Gene ID
Chromosome
position Gene name
Gene
symbol Function
Silenced
in cell line
Promoter
methylation
in cell line
Promoter
methylation
in T
Promoter
methylation
in N
Promoter
methylation
in NDN
AA458849 19q13.2 Serine peptidase
inhibitor, Kunitz
type 2
SPINT2 Serine protease
inhibitor
5/11 4/9 45/118 (CCRCC:
22/74, Pap: 20/44)
2/38 0/6
AA464250 17q21.2 Keratin 19 KTN19 Protein binding,
structural
5/11 4/10 25/66 (CCRCC:
20/51, Pap: 5/15)
3/22 0/6
AA411656 17p13.2 Chemokine (C-X-C
motif) ligand 16
CXCL16 Chemokine
activity
4/11 5/8 26/62 (CCRCC:
20/47, Pap: 6/15)
9/21 0/6
AA496283 11q23.3 Thy-1 cell
surface antigen
Thy1 Integrin binding,
Rho GTPase
activator
5/11 6/7 0/20 0/15 0/6
AA446108 9q34.11 Endoglin
(Osler–Rendu–
Weber syndrome 1)
ENG Protein binding 5/9 4/9 8/9 16/21 6/6
R51912 3q27.3 Somatostatin SST Hormone
activity
5/9 8/8 0/20 0/10 0/6
AA45668 9q33.2 Prostaglandin-
endoperoxide
synthase 1
PTGS1 Peroxidase
activity
6/11 6/9 0/20 0/10 0/6
AA406020 1p36.33 ISG15 ubiquitin-like
modifier
ISG15 Protein binding 8/9 6/9 0/20 0/15 0/6
Abbreviations: CCRCC¼clear cell renal cell carcinoma; N¼adjacent normal tissue; NDN¼non-disease-normal tissue, kidney tissue obtained from non-cancerous kidneys;
Pap¼renal papillary tumour; T¼sporadic RCC tumour. Expression analysis was carried out by semiquantitative RT–PCR. All promoter methylation analysis was performed by
sequencing of bisulphate-modified DNA.
Functional epigenomics in RCC
MR Morris et al
498
British Journal of Cancer (2008) 98(2), 496–501 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sRE-expression of CXCL16 reduces the colony forming
ability of kidney-derived cell lines
The effect of re-expression of CXCL16 on cell growth was assessed
by in vitro colony formation assays. Following transfection of a
wild-type CXCL16 expression plasmid (or empty vector) into
SKRC39 (an RCC cell line, which is heavily methylated at the
CXCL16 promoter), there was a significantly reduced number of
G418 resistant colonies (mean 40.1%, t¼4.16 P¼0.014) compared
to SKRC39 cells transfected with an empty vector control in three
independent experiments (Figure 2).
DISCUSSION
Functional epigenomic screens have proven to be a successful
strategy for identifying epigenetically inactivated TSGs in a
number of different tumour types (Yamashita et al, 2002; Sato
et al, 2003; Lodygin et al, 2005). However, to our knowledge, only
one other functional epigenomic study of RCC has been reported.
Thus, Ibanez de Caceres et al (2006) performed gene expression
microarrays in four RCC cell lines (all different to those analysed
in our study) after treatment with a demethylating agent (5-AZA-2
deoxycytidine) and a histone deacetylation inhibitor (trichostatin
A) and found that between 111 and 170 genes demonstrated a X3-
fold upregulation of expression after treatment in each cell line.
Then they proceeded to analyse 12 genes that were upregulated
X3-fold in at least three of the four cell lines and were expressed in
renal tubular cells (BIRC3, NP, GADD45A, NFKB1A, CYCS, TGM2,
IGFBP1, COL1A1, CTGF, IGFBP1, GDF15 and PLAU) and found
that three genes (IGFBP1, IGFBP3 and COL1A1) demonstrated
tumour-specific methylation and seven genes did not show
promoter methylation. Despite differences in experimental details
and microarrays employed, their findings are similar to those from
our more extensive analysis. Thus, it is clear that although
upregulation of gene expression after demethylation treatment will
often not indicate promoter region hypermethylation, and even if
methylation is present, it may not be tumour specific, this
experimental approach does provide a strategy for identifying
novel TSGs.
Keratin 19, an intermediate filament protein responsible for
the structural integrity of epithelial cells as a gene, frequently
demonstrated promoter methylation in sporadic RCC but not in
normal kidney tissue from RCC patients and non-cancer patients.
Previously, keratin 19 was reported to be downregulated in head
and neck cancers. Furthermore, although re-expression of keratin
19 did not affect the growth rate of transfected cell lines, in vitro
invasiveness after treatment with HGF was reduced after re-
expression (Crowe et al, 1999).
We found that the transmembrane chemokine CXCL16
(Matloubian et al, 2000; Shimaoka et al, 2000; Wilbanks et al,
2001; Shimaoka et al, 2003) was also frequently methylated in RCC
cell lines and in primary tumours but not in normal kidney from
non-cancer controls. Although CXCL16 methylation was detected
in adjacent normal renal tissue from RCC patients with tumour
methylation, this might indicate a premalignant field defect
(as described in bronchial epithelium); however, contamination
by tumour cells cannot be excluded completely. Interestingly,
re-expression of CXCL16 significantly reduced the formation of
kidney cell line colonies.
A significant rationale for identifying RCC-associated hyper-
methylated TSGs is their potential role as biomarkers to identify
high-risk individuals and presymptomatic tumours by analysis of
urine samples (Battagli et al, 2003; Hoque et al, 2004). In this
context, it is valuable to identify both genes that are methylated
early in tumorigenesis (but which may not show tumour-specific
methylation) and also genes that are specific for tumours.
The functional epigenomic approach we pursued, in addition to
identifying genes associated with tumour-specific methylation,
also identified significant numbers of genes that (a) appeared to
demonstrate cell line-specific methylation (SST, PTGS1, ISG15,
THY1) or (b) were upregulated by demethylation but had no
apparent promoter region methylation. The former group,
although apparently not frequently methylated in primary
tumours, might be considered as candidate genes implicated in
progression (assuming that acquisition of methylation in cell
culture might have a growth advantage). In this context, it is
interesting to note that PTGS1 methylation is frequent in prostate
cancer (Bastian et al, 2005), THY1 has been implicated as a
candidate TSG in nasopharyngeal cancer (Lung et al, 2005) and
SST promoter methylation has been described in B90% of
colorectal cancers (Mori et al, 2006).
Genes that were upregulated by demethylation but not
methylated included genes that have been described previously
as TSGs in other cancer types (e.g. BAP1 (Jensen and Rauscher,
1999), IGSF4 (Kikuchi et al, 2006), RRM2 (Gautam and Bepler
(2006)), PMAIP1 (Shibue et al, 2003), claudin-1; (Higashi et al,
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Figure 2 Re-expression of CXCL16 in RCC cells results in growth
suppression. Equal (molar) amounts of empty vector (EV) and pCDNA3.1-
CXCL16 (CXCL16) were transfected into SKRC39 cells. Following
antibiotic selection, surviving colonies were stained. Each experiment was
performed in triplicate and the means of these used to produce the bar
chart. The mean number of colonies counted in the EV plates was taken as
100%. There was a statistically significant reduction of colonies in each of
the CXCL16 transfectants (P¼0.0141).
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s2007) and ICAM1; (Georgolios et al, 2006)). These observations
would be consistent with the hypothesis that expression of these
genes is reactivated secondary to changes in promoter methylation
at upstream regulators. Hence, further analysis of this class of
genes may provide insights into key pathways that are dysregu-
lated in RCC and identify candidate upstream regulators for
epigenetic analysis.
We have reported the identification and systematic analysis of
candidate RCC TSGs identified from a functional epigenomics
screen. To date, the only two functional epigenomic studies
performed in RCC have each analysed four RCC cell lines on arrays
containing o15000 genes, but each have identified novel genes
with tumour-specific methylation. Compared to other genes
reported to be methylated in RCC, SPINT2, CXCL16 and KTN19
are relatively frequently methylated (Figure 3). Therefore, we
suggest that further, more extensive, studies are warranted to
identify additional potential RCC TSGs and methylated biomarkers
for early cancer detection.
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Figure 3 Frequency of gene promoter methylation in RCC. Data were derived from the present study and (Merlo et al, 1995; Dreijerink et al, 2001;
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2006; Dahl et al, 2007; Gumz et al, 2007; Kempkensteffen et al, 2007). Abbreviations: APAF-1, apoptotic protease activating factor; CASP8, caspase 8; CDH1,
cadherin 1; CDH3, cadherin 3; COL1A1, collagen type I, alpha-1; CXCL16, chemokine, cxc motif, ligand 16; DAL-1/4.1B, differentially expressed in
adenocarcinoma of the lung/nonerythroid protein 4.1, brain type 4.1b; DAPK, death-associated protein kinase 1; GSTP1, glutathione-S-transferase, PI;
HOXB13, homoeobox B13; IGFBP1, insulin-like growth factor-binding protein 1; IGFBP3, insulin-like growth factor-binding protein 3; KRT19, keratin 19;
MGMT, methylguanine-DNA methyltransferase; p14, cyclin-dependent kinase inhibitor 2a alternative reading frame; p16, cyclin-dependent kinase inhibitor
2a; PML, acute promyelocytic leukaemia (inducer of); RASSF1, Ras association domain family protein 1; SFRP1, secreted frizzled-related protein 1; SLIT2, slit,
Drosophila, homologue of 2; SPINT2, serine protease inhibitor, Kunitz-type 2; VHL, Von Hippel–Lindau syndrome gene; XAF1, XIAP-associated factor.
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